Canaccord Genuity Reiterates Buy on DexCom (DXCM) Following FDA Approval of DexCom's G5 Mobile
Tweet Send to a Friend
Canaccord Genuity reiterated a Buy rating and $70.00 price target on DexCom (NASDAQ: DXCM) following the company's announced FDA approval ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
